Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

Investors and analysts will be watching closely how Lilly overcomes these obstacles in the changing obesity treatment environment.